Differential actions of the dopamine agonist bromocriptine on growth of SMtTW tumors exhibiting a prolactin and/or a somatotroph cell phenotype: Relation to dopamine D2 receptor expression

Endocrinology

Volumn 140, Issue 1, 1999, Pages 13-21

  Trouillas, Jacqueline ^a   Chevallier, Pascale ^a   Remy, Christine ^a   Rajas, Fabienne ^a   Cohen, Richard ^b   Calle, Aleth ^a   Hooghe Peters, Elisabeth L ^c   Rousset, Bernard ^a  

^a UNIVERSITÉ LYON 1   (France)

^b HÔPITAL NEUROLOGIQUE   (France)

^c VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

BROMOCRIPTINE; COMPLEMENTARY DNA; DOPAMINE 2 RECEPTOR; DOPAMINE RECEPTOR STIMULATING AGENT; MESSENGER RNA; PLACENTA LACTOGEN; PROLACTIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CYTOCHEMISTRY; GENE EXPRESSION; GROWTH HORMONE BLOOD LEVEL; HORMONE SYNTHESIS; IMMUNOASSAY; IMMUNOCYTOCHEMISTRY; IN SITU HYBRIDIZATION; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; PROLACTINOMA; RAT; RECEPTOR BINDING; STATISTICAL ANALYSIS; TUMOR GROWTH;

EID: 0032943178     PISSN: 00137227     EISSN: None     Source Type: Journal    
DOI: 10.1210/endo.140.1.6450     Document Type: Article

References (24)

1. 1. Bevan JS, Webster J, Burke CW, Scanlon MF 1992 Dopamine agonists and pituitary tumor shrinkage. Endocr Rev 13:190-210
2. 2. Pellegrini I, Rasolonjanahary R, Gunz G, Bertrand P, Delivet S, Jedynak CP, Kordon C, Peillon F, Jaquet P, Enjalbert A 1989 Resistance to bromocriptine in prolactinomas. J Clin Endocrinol Metab 69:500-509
3. 3. Luizzi A, Chiodini PG, Botalla L, Cremascoli G, Muller EE, Silvestrini F 1974 Decreased plasma growth hormone (GH) levels in acromegalics following CB 154 (2-Br-alpha-ergocryptine) administration. J Clin Endocrinol Metab 38:910-912
4. 4. Bression D, Brandi AM, Nousbaum A, Le Dafniet M, Racadot J, Peillon F 1982 Evidence of dopamine receptors in human growth hormone (GH)-secreting adenomas with concomitant study of dopamine inhibition of GH secretion in a perifusion system. J Clin Endocrinol Metab 55:589-593
5. 5. Spada A, Sartorio A, Bassetti M, Pezzo G, Giannattasio G 1982 In vitro effect of dopamine on growth hormone release from human GH-secreting pituitary adenomas. J Clin Endocrinol Metab 55:734-740
6. 6. Barkan A 1989 Acromegaly. Diagnosis and therapy. Endocrinol Metab Clin North Am 18:227-331
7. 7. Lamberts SWJ, Klijn JGM, Van Vroonhoven CCJ, Stefanko SZ 1985 Different responses of growth hormone secretion to guanafacine, bromocriptine and thyrotropin-releasing hormone in acromegalic patients with pure growth hormone (GH)-containing and mixed GH/prolactin-containing pituitary adenomas. J Clin Endocrinol Metab 60:1148-1153
8. 8. Bassetti M, Arosio M, Spada A, Brina M, Bazzoni N, Faglia G, Giannattasio G 1988 Growth hormone and prolactin secretion in acromegaly: correlations between hormonal dynamics and immunocytochemical findings. J Clin Endocrinol Metab 67:1195-1204
9. 9. Trouillas J, Girod C, Claustrat B, Joly-Pharaboz MO, Chevallier P 1990 Spontaneous prolactin transplantable tumor in the Wistar/Furth rat (SMtTW): a new animal model of human prolactinoma. Cancer Res 50:4081-4086
10. 10. Trouillas J, Chevallier P, Claustrat B, Hooghe-Peters E, Dubray C, Rousset B, Girod C 1994 Inhibitory effects of the dopamine agonists quinagolide (CV 205-502) and bromocriptine on prolactin secretion and growth of SMtTW pituitary tumors in the rat. Endocrinology 134:401-410
11. 11. Chirgwin JM, Przybyla AE, Mac Donald RJ, Rutter WJ 1979 Isolation of biologically active ribonucleic Acid from sources enriched in ribonuclease. Biochemistry 18:5294-5299
12. 12. White BA, Bancroft FC 1982 Cytoplasmic dot hybridization. Simple analysis of relative mRNA levels in multiple small cell or tissue samples. J Biol Chem 257:8569-8572
13. 13. Delhase M, Rajas F, Verdood P, Remy C, Chevallier P, Velkeniers B, Trouillas J, Hooghe-Peters EL 1995 Prolactin and growth hormone mRNA and protein characterization in SMtTW rat pituitary tumours. J Mol Endocrinol 15:233-243
14. 2 dopamine receptor cDNA. Nature 336:783-787
15. 2 dopamine receptor. Proc Natl Acad Sci USA 86:9762-9766
16. 16. Monsma FJ, Mc Vittie ID, Gerfen CR, Mahan LC, Sibley DR 1989 Multiple dopamine receptors produced by alternative RNA splicing. Nature 342:926-929
17. 17. Sibley DR, Monsma FJ 1992 Molecular biology of dopamine receptors. Trends Pharmacol Sci 13:61-69
18. 18. Bression D, Brandi AM, Martres MP, Nousbaum A, Cesselin F, Racadot J, Peillon F 1980 Dopaminergic receptors in human prolactin-secreting adenomas: a quantitative study. J Clin Endocrinol Metab 51:1037-1043
19. 19. Brue T, Pellegrini I, Priou A, Morange I, Jaquet P 1992 Prolactinomas and resistance to dopamine agonists. Horm Res 38:84-89
20. 20. Delgrange E, Trouillas J, Maiter D, Donckier J, Tourniaire J 1997 Sex-related difference in the growth of prolactinomas: a clinical and proliferation marker study. J Clin Endocrinol Metab 82:2102-2107
21. 2 dopamine receptor isoforms in bromocriptine-resistant prolactinomas. Neuroendocrinology 60:314-322
22. 22. Friedman E, Adams EF, Höög A, Gejman PV, Carson E, Larsson C, De Marco L, Werner S, Fahlbusch R, Nordenskjöld M 1994 Normal structural dopamine type 2 receptor gene in prolactin-secreting and other pituitary tumors. J Clin Endocrinol Metab 78:568-574
23. 23. Vertongen P, Delhase M, Rajas F, Trouillas J, Hooghe-Peters E, Svoboda M, Robberecht P 1996 Pituitary adenylate cyclase-activating polypeptide/vasoactive intestinal polypeptide receptors subtypes are differently expressed in the rat transplanted pituitary tumors (SMtTW) and in the normal gland. J Mol Endocrinol 16:239-248
24. 24. Trouillas J, Girod C 1996 Pathology of pituitary adenomas. In: Landolt AM, Vance ML, Reilly PL (eds) Pituitary Adenomas. Churchill Livingstone Publishers, London, pp 27-46